clear that with erythropoietin it also induces the formation of colonies derived from early erythroid burst-forming units (BFU-E) and from mixed colony-forming units that comprise granulocytes, erythroid cells, macrophages and megakaryocytes (CFU-GEMM or CFU-MIX) (9) (10) (11) (12) (13) (14) . Although human GM-CSF is clearly therefore a multipoietin, confusion has arisen by introducing new terms to describe the expanded target cell range of this and possibly other factors. Not all of the additional effects of these purified CSFs have been confirmed. The factors themselves and their roles in hematopoiesis have been more clearly established in murine species. Table I lists the murine and human factors, including their nomenclature, major biological activities, homologies, and specificities. Several important points should be noted. Firstly, only very recently has a human homologue for murine multi-CSF (interleukin 3, IL3), the factor influencing the proliferation of stem cells and committed progenitors of multiple cell lineages, been identified (15) . Secondly, the CSFs are produced by multiple cell types. Since indirect effects can be produced by accessory cells present in unfractionated cells that are capable of factor production, investigations of the biological activities of these factors can be influenced by the degree of purity of the target cell population obtained. Thirdly, it is apparent from Table I that several factors have overlapping activities. In comparing the actions of the purified hormones it is important to distinguish effects on self-renewal or survival, proliferation, and differentiation. It has not yet been possible to purify normal hematopoietic target cells in sufficient quantities to determine the intracellular biochemical pathways involved and to distinguish differences in the effects ofthe various factors on phases of the cell cycle. There is evidence, however, that at least two and possibly three classes of factors may be important for complete cell development in a number of lineages (16, 17) : class I factors such as multi-CSF and GM-CSF act on pluripotent cells and immature progenitor cells. They are not lineage specific, are required throughout differentiation, are important for selfrenewal and proliferation of these cells and contribute as well to their differentiation. Class II factors (e.g., G-CSF, M-CSF, and erythropoietin, EP) act on more mature progenitor cells, and are only required later during the development of specific cell lineages. They influence proliferation and differentiation of progenitors, and survival of mature cells. At the present time, there is evidence of a third class: a factor that has synergistic activity with either multi-CSF or M-CSF (18) (19) (20) , but no colonystimulating activity (CSA) alone. The factor, termed hematopoietin 1, has been purified from a human bladder carcinoma cell line (19) . The combined stimulus ofthis factor with M-CSF leads to the formation of giant murine macrophage colonies in vitro. The gene for this factor has not been isolated and no analogous human assay for this activity has been described. The biological activities of the five cloned CSFs is presented in (8) .
Highly purified natural or recombinant human GM-CSF stimulates granulocyte/macrophage and eosinophil colony formation in vitro. In addition, when partially purified bone marrow progenitor cultures are initiated with GM-CSF, and EP added 3-5 d later, the combined stimulus induces the formation of colonies derived from BFU-E and CFU-MIX as well (9, 11, 12) . In these experiments, purified bone marrow progenitors are plated at low density (1,000-5,000/ml), and this suggests that GM-CSF can act directly on progenitor cells of all lineages. However, clones initiated in GM-CSF alone and subsequently transferred to either GM-CSF, EP, or GM-CSF + EP have resulted in full maturation of only granulocyte-macrophage and eosinophil colonies (8) , supporting the interpretation that GM-CSF acts directly on the progenitor cells of the latter lineages. BFU-E were not observed after clonal transfer. One interpretation of this result is that the action of GM-CSF on erythroid progenitors is indirect; alternatively, other factor(s) may be necessary for full erythroid (and multipotent) progenitor differentiation. Support for the latter interpretation comes from the observation that GM-CSF rarely induces as many BFU-E-derived colonies in culture as are formed by optimal concentrations of crude sources of CSA such as Mo cell line CM (9) . GM-CSF plateau levels for CFU-GM, eosinophil, and BFU-E colony formation in vitro are -1-5 ng/ml (50-250 pM) with half-maximal stimulation observed at 5-50 pM (8, 9) . The plateau numbers ofBFU-E-derived colonies induced by GM-CSF are usually -2/3 of the number observed with Mo CM. The recent discovery of a human multi-CSF (15) has shown that at least two factors affect the proliferation of early erythroid progenitors. It will be important to determine whether combinations of these two factors and/or other purified factors can act additively or synergistically in these in vitro cultures. (4) and is a potent activator of neutrophils and eosinophils, inducing antibody dependent cytotoxicity for human target cells (2, 3) . It increases neutrophil phagocytic activity (8) . Some of these functional changes may be related to GM-CSF-induced increase in the cell surface expression of a family of antigens that function as cell adhesion molecules (6) . The increase in antigen expression is rapid and associated with increased aggregation of neutrophils: both are maximal at the migration inhibitory concentration of 500 pM. The granulocyte-granulocyte adhesion can be inhibited by an antigen-specific monoclonal antibody. A similar pattern ofchanges was noted when purified monocytes were examined (Bierer, B., and C. Sieff. Unpublished observation.).
Granulocyte colony-stimulating factor (G-CSF) Human G-CSF was first purified to apparent homogeneity from medium conditioned by the human bladder carcinoma cell line 5637 (23 The gene has five exons and four introns. Two cDNAs that represent the 177 amino acid protein and the 174 amino acid protein with the 36-38 deletion were isolated. Analysis indicated that alternative use of two donor splice sites nine nucleotides apart at the 5' end of intron 2 is responsible for the production oftwo different mRNAs for human G-CSF. Both RNAs encode biologically active G-CSF, but differences in bioactivity may exist (25a). It is not known whether two forms of native G-CSF exist in the human. Neuraminidase and O-glycanase treatment of natural purified G-CSF (25) reduced the molecular mass of the protein from 19,600 to 18,800 D, suggesting that the difference in molecular mass is due to O-glycosylation. There are no potential N-glycosylation sites. Southern hybridization of DNA from normal human leukocytes digested with any of four restriction enzymes and probed with a labeled G-CSF cDNA insert showed a single fragment, suggesting that human G-CSF is encoded by a single gene (25) .
Initial reports using natural purified human G-CSF or the recombinant hormone suggested that in addition to an effect on granulocyte-macrophage progenitors, G-CSF, in the presence of erythropoietin, induced the formation of colonies derived from BFU-E and CFU-MIX as well (23) . In these experiments, the G-CSF was tested on low density bone marrow cells. These results were not confirmed when enriched bone marrow progenitor cells were used instead, and the G-CSF showed a predominant effect on granulocyte progenitors (26 and Sieff, C. A. Unpublished observations.). These data suggest that the reported effects of G-CSF on erythroid and mixed-colony progenitors may be indirect. Murine G-CSF stimulates predominantly granulocyte colony formation from murine bone marrow cells (27) , and also has the capacity to induce differentiation of murine myelomonocytic leukemic cell lines such as WEHI-3BD' (28) .
Partially purified human G-CSF (29, 30) has properties analogous to murine G-CSF, and the human and murine G-CSF molecules show almost complete biological and receptor-binding crossreactivities to normal and leukemic murine and human cells (30) . Purified murine G-CSF also stimulates antibody dependent cell-mediated cytotoxicity of both murine and human neutrophils (31 The cDNA sequence predicts a hydrophobic region of 23 amino acids that could signify transmembrane insertion (36) . This is consistent with studies that suggest that membrane and secretory forms of CSF-1 may exist (38, 38a) .
Recombinant or purified human M-CSF induces the for-mation of colonies derived predominantly from macrophage progenitors (39) , and it is more active on murine than on human target cells. In view ofthe reported synergism of murine M-CSF with hematopoietin 1, it is possible that human M-CSF requires the presence of another factor(s) for optimal stimulation of human target cells. The effect on human granulocyte macrophage progenitors may be indirect (40) . Purified native murine M-CSF increases plasminogen-dependent fibrinolytic activity of mouse peritoneal macrophages (40a).
Erythropoietin
The EP molecule was first purified to apparent homogeneity from the urine ofpatients with aplastic anemia (41 (59, 60) . Low numbers of GM-CSF receptors are expressed by mature polymorphonuclear neutrophils and by the myeloid leukemic cell lines KGl and HL60. Reported affinity constants range from 109 to 1012 M`and only one class of binding sites has been reported, in contrast to one of the murine GM-CSF binding studies in which both high and low affinity classes of receptors were reported (49) .
Recent evidence (61) suggests strongly that the M-CSF receptor and the protooncogene product c-fins are closely related and possibly identical proteins: both proteins are of similar size (165,000 D) and exhibit tyrosine kinase activity; an antibody to c-fins precipitates a protein that is phosphorylated on tyrosine in the presence of purified M-CSF, and 1251 M-CSF can be recovered from immunoprecipitates of receptor-membrane extracts. These data are of considerable interest and provide new evidence linking oncogenes and growth factors: v-erb B encodes a protein that is a truncated form ofthe epidermal growth factor receptor (62), and c-sis codes for a polypeptide chain of platelet Thus, it will be important to identify the producer cells in the bone marrow microenvironment and their relationship to developing progenitors by using in situ RNA hybridization techniques. Very little is known about the mechanism by which the growth factors induce cell proliferation and differentiation; one hopes that the receptors for all the human growth factors will soon be identified, and their mechanism of activating cells and relationship, if any, to known cellular oncogenes investigated. The majority of myeloid leukemic blasts that are capable of colony formation in culture are dependent on the addition of exogenous CSFs present in conditioned media for proliferation in vitro (90) . In most cases GM-CSF can substitute for some, but not all, sources of conditioned media. GM-CSF appears to be one, but not the only factor capable of stimulating leukemic cell proliferation, and it will be important to identify other factors capable of fulfilling this role. Only a proportion of myeloid leukemic cells appear capable of "autonomous" proliferation in vitro, and therefore the simple model of factor secretion and autostimulation by leukemic blasts appears unlikely to be an important mechanism in the emergence of a leukemic clone. However, a surprising number ofacute myeloid leukemic blasts contain GM-CSF mRNA, and a proportion ofthese secrete CSF as well (90a). A defect leading to uncoupling of ligand-receptor mediated proliferation with differentiation is likely to exist, but in some cases, expression of CSF genes by leukemic cells could promote the expansion of leukemic clones in vivo. A detailed comparison of receptor number and function in normal and leukemic cells is at present difficult because of the inability to obtain large numbers of purified normal progenitors, although progress in this area is encouraging (12) .
Finally, it will be important to establish the therapeutic roles, ifany, for GM-CSF, erythropoietin, and the other growth factors as they become available in large quantities. GM-CSF may be useful in shortening the period of aplasia associated with ablative chemoradiotherapy for bone marrow transplantation, and could stimulate hematopoiesis in some patients with hypoplastic bone marrows. G-CSF may be useful as a stimulus of granulopoiesis in infected patients. In addition, since it has been shown to be capable of inducing the differentiation of leukemic blasts (91) , it will be evaluated for a therapeutic role in this disease. Erythropoietin is presently being tested as treatment for anemia uremic patients; the results are extremely promising, and trials are being planned to evaluate the hormone in other anemias.
The advances in molecular biology that have led to the production ofboth highly purified CSF recombinant gene products and specific probes for their presence in tissues have revolutionized experimental hematology. During the next few years, these tools should provide the opportunity for investigators to answer many ofthe intriguing questions in relation to CSF production, mechanism of action in normal and leukemic cells, and the therapeutic role in patients suffering from defects of production of blood cells.
